Repligen Corporation $RGEN Holdings Lowered by Royce & Associates LP

Royce & Associates LP trimmed its position in shares of Repligen Corporation (NASDAQ:RGEN) by 10.2% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 156,976 shares of the biotechnology company’s stock after selling 17,818 shares during the quarter. Royce & Associates LP’s holdings in Repligen were worth $30,175,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in the company. ABS Investment Management LLC purchased a new position in Repligen in the 2nd quarter valued at $191,016,000. CoreCap Advisors LLC boosted its stake in Repligen by 1,275.0% during the 3rd quarter. CoreCap Advisors LLC now owns 275 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 255 shares during the last quarter. Farther Finance Advisors LLC grew its holdings in shares of Repligen by 35.5% during the third quarter. Farther Finance Advisors LLC now owns 374 shares of the biotechnology company’s stock worth $72,000 after buying an additional 98 shares in the last quarter. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Repligen during the second quarter worth $52,000. Finally, Heritage Family Offices LLP acquired a new stake in shares of Repligen in the third quarter valued at about $80,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Trading Up 0.8%

NASDAQ RGEN traded up $1.27 on Friday, reaching $167.79. 510,110 shares of the company were exchanged, compared to its average volume of 1,292,036. The company has a current ratio of 9.88, a quick ratio of 8.43 and a debt-to-equity ratio of 0.27. The business’s fifty day moving average price is $177.15 and its 200 day moving average price is $145.67. The stock has a market capitalization of $10.73 billion, a P/E ratio of -798.96, a price-to-earnings-growth ratio of 2.85 and a beta of 1.11. Repligen Corporation has a fifty-two week low of $100.99 and a fifty-two week high of $198.87.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, October 27th. The biotechnology company reported $0.53 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.46 by $0.07. Repligen had a positive return on equity of 5.49% and a negative net margin of 1.47%. The business had revenue of $209.31 million during the quarter, compared to the consensus estimate of $206.70 million. During the same period last year, the company earned $0.46 EPS. The company’s revenue for the quarter was up 10.9% on a year-over-year basis. Analysts forecast that Repligen Corporation will post 2.07 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently weighed in on RGEN. UBS Group reissued a “buy” rating on shares of Repligen in a research note on Tuesday, September 29th. Wells Fargo & Company upped their price objective on shares of Repligen from $180.00 to $185.00 and gave the company an “overweight” rating in a research note on Thursday, July 30th. JPMorgan Chase & Co. upped their price objective on shares of Repligen from $165.00 to $175.00 and gave the company an “overweight” rating in a research note on Wednesday, July 29th. Royal Bank Of Canada increased their price objective on shares of Repligen from $185.00 to $200.00 and gave the company an “outperform” rating in a report on Wednesday, October 28th. Finally, Barclays raised their target price on shares of Repligen from $175.00 to $225.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 7th. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $178.57.

About Repligen

Repligen is a life sciences company that develops and supplies technologies used in the manufacture of biologic medicines. Its products support biopharmaceutical companies and contract manufacturers in producing treatments such as monoclonal antibodies, vaccines and gene therapies. The company’s offerings span several stages of bioprocessing, including filtration, chromatography, fluid management and process analytics. Its products include filtration systems and single-use components, chromatography solutions and instruments that help monitor and control manufacturing processes.